GlassScriptPhysician profile
Maria Kent
NPI 1992781298
$11,448.38
in general payments reported to CMS, 2019-2025
51 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,844 · 2020: $1,154 · 2021: $1,156 · 2022: $1,430 · 2023: $1,766 · 2024: $2,453 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,824 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,824.00 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,864.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,438.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,271.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $946.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $846.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $718.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $642.78 | 2019-2025 | Otezla, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $346.63 | 2023-2025 | |
| Astellas Pharma US INC | $302.12 | 2019-2025 | Veozah |
| Abbott Laboratories | $250.09 | 2022-2025 | Freestyle Libre 3, Infinity |
| Kowa Pharmaceuticals America, INC. | $246.33 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $206.60 | 2019-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $188.15 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.84 | 2020-2025 | Xifaxan |
| Allergan, INC. | $167.79 | 2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.